AzTrials
AzTrials

Macular EdemaNCT01485575

Mechanical Properties of the Internal Limiting Membrane and Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy

An observational study of Macular Edema, run by University Hospital, Basel, Switzerland at 3 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Intravitreal dyes are intended to make the surgical extraction of the Internal limiting membrane (ILM) safer and more complete. However, the search for an adequate vitaly dye is ongoing. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Macular Edema
What is being tested?
Use of intraoperative filters in vitrectomy
Type of treatment
Surgery or procedure
How many people
50 participants
Where
3 sitesin 2 countries
Study dates
Nov 2011to Jun 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Consecutive patients treated with Chromovitrectomy at 3 tertiary care hospitals.

Who may be able to join

  • Over 18 Years of age
  • No other chromovitrectomy in previous 6 months
  • Only one of three vitaly dyes used intraoperatively (BBG, ICG or TB)

Who cannot join

  • Previous chromovitrectomy during last 6 months
  • Pregnant patients
  • Patients under 18 years of age

Trial locations and contacts

3 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Paul B. Henrich, MD, Ph.D. contact

+41 91 9932727

henrich.oftacentro@hin.ch

3 sites in 2 countries

Switzerland2 sites, 2 recruiting
  • Oftacentro

    Paradiso, Canton Ticino, 6900

    Paul B Henrich, MD, +41 9932727, bernhard.henrich@ksw.ch

    Recruiting
  • St. Gallen Hospital

    Sankt Gallen, Canton of St. Gallen, 9007

    Christophe Valmaggia, MD, +41 71 494 11 11, Christophe.Valmaggia@kssg.ch

    Recruiting

Other trials in Switzerland

Austria1 site, 1 recruiting
  • General Hospital Linz

    Linz, 4010

    Rupert W Strauss, MD, +43 732 7806 - 73425, rupert.strauss@akh.linz.at

    Recruiting

Other trials in Austria

About this study

Intravitreal dyes are intended to make the surgical extraction of the Internal limiting membrane (ILM) safer and more complete. However, the search for an adequate vitaly dye is ongoing. The most commonly used vital dye is Indocyanine green (ICG), although it is not approved for intravitreal use and has been associated with ocular toxicity. The reason for its continued popularity seems to be that it stains the ILM better than the approved and less toxic alternative substances Brilliant Blue G (BBG) and Trypan blue (TB). According to anecdotal reports from surgeons, another reason for ICGs popularity may be the fact that it seems to make ILM removal easier. Ultimately, the intention of the investigators research is to identify possible modifications to existing dyes to reach improved intraoperative dye utility combined with a favorable safety profile.

Protocol was amended and approved concerning additional use of basal membrane of deceased donors.

Read the detailed description

The human retina is a light-sensitive tissue lining the inner surface of the posterior segment of the eye. It is a complex, layered structure containing the photoreceptors and several layers of neurons. Proper retinal function requires a smooth interface between the retina and the adjoining vitreous body (vitreous), a gelatinous and transparent substance occupying the cavity of the posterior ocular segment. The innermost of the retinal layers, a basement membrane called Inner limiting membrane (ILM), represents the boundary between the retina and the vitreous. Excessive contact between the ILM and the vitreous leads to vitreoretinal traction and represents a common cause of ocular pathology: The vitreous adheres to the ILM and shearing forces are conveyed to the retina. Vitreoretinal traction concentrates around the Macula lutea, the small area in the center of the retina which is responsible for central vision. It may be associated with significant visual disturbance as it creates retinal folds, provokes retinal edema and epiretinal metaplastic membranes through the liberation of inflammatory messenger substances and may ultimately result in the formation of macular holes. Macular holes tend to lead to sudden and often complete loss of central vision.

Removal of the vitreous (vitrectomy) may improve vitreoretinal traction, but a complete relief of traction is only achieved if the ILM is removed from the retina in the area around the macula: At the end of vitrectomy, the surgeon grasps the ILM with a fine forceps and carefully peels it off the underlying retinal layers. This procedure is extremely delicate, as the ILM is transparent, extremely thin and in direct contact with highly vulnerable retinal structures. Vital dyes have been employed to make the ILM more visible and because some dyes have been described to improve "grip" of the ILM during its extraction. The most commonly used dye, Indocyanine green (ICG) is not approved for intravitreal use and a discussion on possible toxic side effects is ongoing. The approved alternative substance Brilliant blue G is employed only by a minority of vitreoretinal surgeons. It is our hypothesis, that the popularity of ICG is due to superior staining capacity and a stiffening effect which may make ILM removal easier for the surgeon.

The first goal of this interdisciplinary and translational project, integrating Medical physics, Biomedical engineering, Nanosciences, Biochemistry, Neurobiology, Medical Image analysis and Clinical ophthalmology is to assess the biophysical properties of the ILM and the possible effects of existing dyes in terms of staining behavior and their influence on ILM "grip". In a second step, the project will analyze how new application protocols and the introduction of novel components to the molecular structure of vital dyes can improve staining as well as "ILM-grip" while guaranteeing favorable toxicity profiles Hypotheses

  1. A novel "Heavy BBG" (BBG D2O) stains the ILM better than conventional BBG. A replacement of part of the water molecules with Deuterium Oxide (D20) in the BBG solvent increases the dye's specific gravity. After injection into the vitreous, this new preparation (BBG D2O) would collect on the retinal surface, increasing local concentration and retinal exposure. We hypothesize that this alteration of the BBG molecular structure could improve staining properties without compromising its favorable toxicity profile. This new BBG has already been introduced by the manufacturer, but its intraoperative usefulness has not been objectively examined.
  2. The use of intraoperative light filters improves the recognizability of the contrasts generated by vital dyes. Most endoillumination lighting systems are equipped with light filters, originally intended to reduce intraoperative light toxicity. Anecdotal reports by numerous surgeons indicate, however, that the use of some filters improves the recognizability of the stained ILM. The green filter is regarded as particularly useful for this purpose. A systematic analysis of the effects of light filters on the usefulness of intravitreal dyes has not been undertaken to date.
  3. ICG and TB's photochemical properties improve "ILM grip" through an ILM cross-linking effect resulting in an alteration of ILM material properties. We expect increased intra-operative ILM compressive and tensile stiffness and reduced ILM thickness in Atomic force microscopy examinations, explaining why many surgeons describe facilitated intraoperative manipulation and extraction of the ILM. BBG is not known to dispose of photochemical properties and should not influence ILM material properties.
  4. Novel Modified ICG preparation stains equally well but is less toxic An alteration of the molecular structure in a way such that photochemical properties of the substance would be largely eliminated would strongly reduce oxidative stress and retinal toxicity. Synthetization of such a preparation is being prepared by our group. Staining properties are different from the original preparation in that the absorption maximum is shifted towards shorter wavelengths and the staining effect is bluish rather than green. The substance's affinity to the ILM its staining strength and its toxicity have not been studied, to date.
Conditions
Macular Edema
Being tested
Use of intraoperative filters in vitrectomy
Keywords
Chromovitrectomy, Indocyanine green, ICG, Brilliant Blue G, BBG, Trypan blue, TB, Internal limiting membrane, ILM
Medical subject headings
Macular Edema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Use of intraoperative filters in vitrectomyProcedure or surgery

    Also called Stellaris PC surgical (Bausch&Lomb surgical,Aliso Viejo,CA)

    During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes

Study groups in NCT01485575
Study groupRoleWhat they receive
Filter use during vitrectomyNot described
Receives: Procedure: Use of intraoperative filters in vitrectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ILM thickness, stiffness and roughness

    Measurements under the Atomic force microscope will show wether the use of ICG or BBG influences material properties of the ILM (for example, an increased stiffness may explain a better "grip").

    Measured: No further patient contact is required after surgery. Analysis of the specimens may take up to one year

Secondary outcomes (1)
  1. Contrast between the stained ILM and the underlying tissue

    Intraoperative videos will be analysed to understand under which circumstances vital dyes produce the best contrast visible to the human eye

    Measured: No further patient contact is required after surgery. Analysis of the video frames may take up to one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Dec 2011 (estimated)
  2. Study startNov 2011
  3. Primary completionJun 2028 (estimated)
  4. Study completionJun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01485575
Sponsor's protocol ID
ILM-AMF2
Status last verified
Feb 2025
First submitted
28 Nov 2011
Last updated
13 Feb 2025
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Macular Edema, run by University Hospital, Basel, Switzerland at 3 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Switzerland, Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Paul B. Henrich, MD, Ph.D. (+41 91 9932727, henrich.oftacentro@hin.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ILM thickness, stiffness and roughness (time frame: No further patient contact is required after surgery. Analysis of the specimens may take up to one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in